4.5 Article

Rosacea: New Concepts in Classification and Treatment

期刊

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
卷 22, 期 4, 页码 457-465

出版社

ADIS INT LTD
DOI: 10.1007/s40257-021-00595-7

关键词

-

向作者/读者索取更多资源

Rosacea is a chronic inflammatory skin condition that primarily affects the face and can greatly impact the quality of life and self-esteem of individuals. In addition to general skincare, there are various treatment options available, both topical and systemic, to address the different features of the condition. Ongoing research is focusing on understanding the underlying mechanisms and developing new therapeutic interventions.
Rosacea is a chronic inflammatory dermatosis mainly affecting the cheeks, nose, chin, and forehead. Rosacea is characterized by recurrent episodes of flushing or transient erythema, persistent erythema, phymatous changes, papules, pustules, and telangiectasia. The eyes may also be involved. Due to rosacea affecting the face, it has a profound negative impact on quality of life, self-esteem, and well-being. In addition to general skin care, there are several approved treatment options available for addressing these features, both topical and systemic. For some features, intense pulse light, laser, and surgery are of value. Recent advances in fundamental scientific research have underscored the roles of the innate and adaptive immune systems as well as neurovascular dysregulation underlying the spectrum of clinical features of rosacea. Endogenous and exogenous stimuli may initiate and aggravate several pathways in patients with rosacea. This review covers the new phenotype-based diagnosis and classification system reflecting pathophysiology, and new and emerging treatment options and approaches. We address new topical and systemic formulations, as well as recent evidence on treatment combinations. In addition, ongoing studies investigating novel therapeutic interventions will be summarized.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dermatology

The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry

Annelie H. Musters, Conor Broderick, David Prieto-Merino, Andrea Chiricozzi, Giovanni Damiani, Ketty Peris, Sandipan Dhar, Abhishek De, Esther Freeman, Bernd W. M. Arents, Tim Burton, Angela Leigh-Ann L. Bosma, Ching-Chi Chi, Godfrey Fletcher, Aaron M. Drucker, Kenji Kabashima, Emilie F. de Monchy, Maitreyee Panda, Dmitri Robert Wall, Christian Vestergaard, Emmanuel Mahe, Laura Bonzano, Leila Kattach, Maddalena Napolitano, Maria Fernanda Ordonez-Rubiano, Eva Haufe, Cataldo Patruno, Alan D. Irvine, Phyllis Spuls, Carsten Flohr

Summary: Limited data suggest that patients with atopic dermatitis (AD) receiving systemic immunomodulatory treatments have a lower risk of severe COVID-19 complications. Monotherapy with dupilumab is associated with lower hospitalization rates compared to other therapies. However, combination systemic treatments, particularly those including systemic corticosteroids, have the highest risk of severe COVID-19.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Review Allergy

Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review

Conor Broderick, Stefanie Ziehfreund, Karin van Bart, Bernd Arents, Kilian Eyerich, Stephan Weidinger, Joseph Rastrick, Alexander Zink, Carsten Flohr, BIOMAP Consortium

Summary: Biomarkers associated with the development of comorbidities in atopic dermatitis (AD) patients have been inconsistently reported, and there is a lack of high-quality studies. Commonly reported biomarkers include filaggrin mutations and allergen specific-IgE, while promising biomarkers include specific-IgE and/or skin prick tests for predicting asthma development, and genetic polymorphisms for predicting eczema herpeticum occurrence.

ALLERGY (2023)

Editorial Material Dermatology

Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis

Bernd W. M. Arents

BRITISH JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Management of Acne Vulgaris With Trifarotene

Jerry Tan, Rajeev Chavda, Hilary Baldwin, Brigitte Dreno

Summary: Trifarotene is a recently approved topical retinoid for acne, acting selectively on retinoic acid receptor (RAR) gamma. It reduces hyperkeratinization and inflammation by increasing keratinocyte differentiation, inhibiting leukocyte migration, toll-like receptors, and Activator Protein (AP)-1. Clinical trials have demonstrated its safety and efficacy in reducing comedones and papules/pustules, particularly in truncal acne. This review provides an overview of the data supporting trifarotene's use in acne management.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2023)

Letter Dermatology

First update of the living European guideline (EuroGuiDerm) on atopic eczema

A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. C. Pinton, S. Christen-Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gaspar, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, C. Roxburgh, E. Serra-Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, C. Flohr

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Editorial Material Dermatology

The future is now: the Global Atopic Dermatitis Atlas (GADA)

Bernd W. M. Arents, Esther J. van Zuuren, Olivia Hughes, Zbys Fedorowicz, Carsten Flohr

Summary: The International League of Dermatological Societies launched the Global Atopic Dermatitis Atlas (GADA) in 2022 to address the disparities in prevalence and disease burden of atopic dermatitis (AD) worldwide, particularly in low- and middle-income settings where data is lacking. The recent Global Report on Atopic Dermatitis serves as a baseline. Moving forward, GADA will serve as a central hub for AD burden data by conducting regular systematic evidence syntheses and fieldwork in understudied populations.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Letter Infectious Diseases

Guideline-based intervention improves the quality of antibiotic allergy registration in a hospital setting

Chiara van der Worp, Tara Middeldorp, Laura Kuijpers, Jonna Bank, Lisa Dol, Martha van der Beek, Esther J. van Zuuren, Bart Hendriks, Leo Visser, Mark de Boer, Merel Lambregts

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Article Allergy

Frequency and clinical relevance of contact allergy in dental patients

Malak Al-Gawahiri, Thomas Rustemeyer, Sylvie M. Franken, Esther J. van Zuuren, Norbertus A. Ipenburg

Summary: This study investigates the frequency and clinical relevance of contact allergy in dental patients through patch testing. Results show that clinically relevant patch test reactions were frequently seen in dental patients. However, further studies are needed to confirm these findings.

CONTACT DERMATITIS (2023)

Letter Dermatology

Dietary habits and nutritional intake in Dutch adults with atopic dermatitis: A cross-sectional study

F. L. de Boer, B. W. M. Arents, Z. Kowalska, P. P. G. Simons, N. M. de Roos, P. M. Kemperman, T. Rustemeyer

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Review Dermatology

Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis

Yael Renert-Yuval, Ester Del Duca, Bernd Arents, Robert Bissonnette, Aaron M. Drucker, Carsten Flohr, Emma Guttman-Yassky, Dirkjan Hijnen, Kenji Kabashima, Yael A. Leshem, Amy S. Paller, Jonathan I. Silverberg, Eric L. Simpson, Phyllis Spuls, Christian Vestergaard, Andreas Wollenberg, Alan D. Irvine, Jacob P. Thyssen

Summary: This study evaluated the existing data on the treat-to-target (T2T) approach in dermatology, with a specific focus on atopic dermatitis (AD). The results showed that the T2T approach may be a useful tool in simplifying therapeutic goals and managing AD, but its application in AD is still in the early stages and requires a multidisciplinary approach and involvement of various stakeholders.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin

Delphine Kerob, Anna Czermanska, Ewa M. Karamon, Alain Moga, Guillaume Lecerf, Margot Niore, Guenaelle Le Dantec, Caroline Le Floc'h, Jerry Tan

Summary: This study aimed to assess the benefits of a skincare product for individuals with an allergic background or sensitive skin. The results showed that the product significantly reduced skin intolerance and sensitivity, improved skin hydration, and received high satisfaction and tolerance from users.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

Letter Dermatology

Benefits of a dermocosmetic regimen in the management of local side effects triggered by a topical retinoid-based acne treatment

Ewa Karamon, Anna Czermanska, Delphine Kerob, Ann' Laure Demessant, Guenaelle Le Dantec, Caroline le Floc'h, Jerry Tan

JOURNAL OF COSMETIC DERMATOLOGY (2023)

暂无数据